Chronic lung diseases, including cystic fibrosis, non-cystic fibrosis bronchiectasis, non-tuberculosis mycobacteria (NTM) lung disease, and COPD, affect hundreds of millions worldwide and progressively worsen due to cycles of inflammation and infection. This leads to breathing difficulties, frequent hospitalizations, and a decline in quality of life.

Vast Therapeutics is developing targeted therapies designed to break the cycle of inflammation and infection in chronic respiratory diseases. Their approach focuses on addressing the underlying causes of conditions like cystic fibrosis, non-CF bronchiectasis, NTM lung disease and COPD with the goal of improving patient outcomes and quality of life. The company's pipeline includes programs in lead optimization, preclinical, Phase 1, Phase 2, and Phase 3 stages of development.

Focus on therapies for Cystic Fibrosis, Non-CF Bronchiectasis, NTM Lung Disease and COPD.

Pipeline includes programs in lead optimization, preclinical, Phase 1, Phase 2, and Phase 3 stages of development.

Aims to address the root causes of chronic respiratory diseases.

The primary target audience includes individuals suffering from chronic respiratory diseases such as cystic fibrosis, non-cystic fibrosis bronchiectasis, non-tuberculosis mycobacteria (NTM) lung disease, and COPD.